| TORNTPHARM | Peers | Sector | |
|---|---|---|---|
Market Cap | 1,101.6 B | 336.5 B | 5.452 B |
Price % of 52 Week High | 90.6% | 73.6% | 60.4% |
Dividend Yield | 1.0% | 0.7% | 0.0% |
Shareholder Yield | 2.2% | 1.0% | -0.7% |
1 Year Price Total Return | 29.4% | 7.5% | -12.3% |
Beta (5 Year) | 0.26 | 0.39 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Mar-23 | Mar-24 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 96,202 | 107,278 | 113,018 | 27,320 | 28,090 |
| Operating Income | 21,400 | 25,724 | 28,554 | 6,560 | 7,150 |
| Net Profit | 12,452 | 16,564 | 18,624 | 4,430 | 5,030 |
| Diluted EPS | 36.79 | 48.94 | 55.03 | 13.10 | 14.88 |
| EBITDA | 28,026 | 33,249 | 36,753 | 8,217 | 9,031 |
| Balance Sheet | |||||
| Cash & ST Invest. | 7,228 | 10,040 | 12,350 | 7,900 | 12,350 |
| Current Assets | 53,292 | 56,115 | |||
| Total Assets | 150,119 | 150,606 | |||
| Current Liabilities | 54,473 | 54,253 | |||
| Total Liabilities | 88,138 | 82,044 | |||
| Total Equity | 61,981 | 68,562 | 75,040 | 67,070 | 75,040 |
| Total Debt | 54,148 | 40,394 | 31,260 | 44,890 | 31,260 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 23,681 | 32,661 | |||
| Cash From Investing | (24,153) | (1,679) | |||
| Cash From Financing | 774 | (27,796) | |||
| Free Cash Flow | 17,942 | 28,333 | 29,293 | 0.00 | - |